Aytu BioPharma to Report Fiscal 2026 Second Quarter Operational and Financial Results on February 3, 2026
-
Colombia leader offers talks to end trade war with Ecuador
-
Former Masters champ Reed returning to PGA Tour from LIV
-
Norway's McGrath tops first leg of Schladming slalom
-
Iraq PM candidate Maliki denounces Trump's 'blatant' interference
-
Neil Young gifts music to Greenland residents for stress relief
-
Rubio upbeat on Venezuela cooperation but wields stick
-
'No. 1 fan': Rapper Minaj backs Trump
-
Fear in Sicilian town as vast landslide risks widening
-
'Forced disappearance' probe opened against Colombian cycling star Herrera
-
Seifert, Santner give New Zealand consolation T20 win over India
-
King Charles III warns world 'going backwards' in climate fight
-
Minneapolis activists track Trump's immigration enforcers
-
Court orders Dutch to protect Caribbean island from climate change
-
Sterling agrees Chelsea exit after troubled spell
-
Rules-based trade with US is 'over': Canada central bank head
-
Lucas Paqueta signs for Flamengo in record South American deal
-
Holocaust survivor urges German MPs to tackle resurgent antisemitism
-
'Extraordinary' trove of ancient species found in China quarry
-
Villa's Tielemans ruled out for up to 10 weeks
-
Google unveils AI tool probing mysteries of human genome
-
UK proposes to let websites refuse Google AI search
-
'I wanted to die': survivors recount Mozambique flood terror
-
Trump says 'time running out' as Iran threatens tough response
-
Trump issues fierce warning to Minneapolis mayor over immigration
-
Anglican church's first female leader confirmed at London service
-
Germany cuts growth forecast as recovery slower than hoped
-
Amazon to cut 16,000 jobs worldwide
-
One dead, five injured in clashes between Colombia football fans
-
Greenland dispute is 'wake-up call' for Europe: Macron
-
Dollar halts descent, gold keeps climbing before Fed update
-
US YouTuber IShowSpeed gains Ghanaian nationality at end of Africa tour
-
Sweden plans to ban mobile phones in schools
-
Turkey football club faces probe over braids clip backing Syrian Kurds
-
Deutsche Bank offices searched in money laundering probe
-
US embassy angers Danish veterans by removing flags
-
Netherlands 'insufficiently' protects Caribbean island from climate change: court
-
Fury confirms April comeback fight against Makhmudov
-
Susan Sarandon to be honoured at Spain's top film awards
-
Trump says 'time running out' as Iran rejects talks amid 'threats'
-
Spain eyes full service on train tragedy line in 10 days
-
Greenland dispute 'strategic wake-up call for all of Europe,' says Macron
-
'Intimidation and coercion': Iran pressuring families of killed protesters
-
'Pride of the entire nation': Israel holds funeral for last Gaza hostage
-
Europe urged to 'step up' on defence as Trump upends ties
-
Aki a doubt for Ireland's Six Nations opener over disciplinary issue
-
West Ham sign Fulham winger Traore
-
Relentless Sinner sets up Australian Open blockbuster with Djokovic
-
Israel prepares to bury last Gaza hostage
-
Iran rejects talks with US amid military 'threats'
-
Heart attack ends iconic French prop Atonio's career
NYSE - LSE
| SCS | 0.12% | 16.14 | $ | |
| CMSC | -0.72% | 23.631 | $ | |
| RBGPF | 0% | 82.4 | $ | |
| CMSD | -0.19% | 24.05 | $ | |
| RYCEF | -3.31% | 16.6 | $ | |
| RIO | -0.04% | 92.875 | $ | |
| GSK | -2.09% | 49.758 | $ | |
| BTI | -0.82% | 59.85 | $ | |
| BCC | -1.52% | 80.52 | $ | |
| AZN | -2.39% | 93.37 | $ | |
| BCE | -0.67% | 25.35 | $ | |
| RELX | -2.65% | 37.37 | $ | |
| NGG | 0.12% | 84.41 | $ | |
| JRI | -5.27% | 12.995 | $ | |
| VOD | 0.21% | 14.53 | $ | |
| BP | -0.12% | 37.575 | $ |
Aytu BioPharma to Report Fiscal 2026 Second Quarter Operational and Financial Results on February 3, 2026
DENVER, CO / ACCESS Newswire / January 27, 2026 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (Nasdaq:AYTU), a pharmaceutical company focused on advancing innovative medicines for complex central nervous system diseases to improve the quality of life for patients, will report its operational and financial results for its second quarter of fiscal 2026, after the market close on Tuesday, February 3, 2026. The Company has scheduled a conference call and webcast that same day, Tuesday, February 3, 2026, at 4:30 p.m. Eastern time, to review the results followed by a question and answer session.
Conference Call Details
Date and Time: Tuesday, February 3, 2026, at 4:30 p.m. Eastern time.
Call-in Information: Interested parties can access the conference call by dialing (888) 506-0062 for United States callers or +1 (973) 528-0011 for international callers and using the participant access code 567381.
Webcast Information: The webcast will be accessible live and archived at https://www.webcaster5.com/Webcast/Page/2142/53322, and accessible on the Investors section of the Company's website at https://investors.aytubio.com/ under Events & Presentations.
Replay: A teleconference replay of the call will be available until February 17, 2026, at (877) 481-4010 for United States callers or +1 (919) 882-2331 for international callers and using replay access code 53322.
About Aytu BioPharma
Aytu is a pharmaceutical company focused on advancing innovative medicines for complex central nervous system diseases to improve the quality of life for patients. The Company's prescription products include EXXUA™ (gepirone) extended-release tablets (see Full Prescribing Information, including Boxed WARNING) for the treatment of major depressive disorder (MDD), and treatments for attention deficit-hyperactivity disorder (ADHD). Aytu is committed to delivering the Company's medications through best-in-class patient access programs that help to enable optimal patient outcomes. For more information, please visit aytubio.com or follow us on LinkedIn.
Contacts for Investors
Ryan Selhorn, Chief Financial Officer
Aytu BioPharma, Inc.
[email protected]
Robert Blum
Lytham Partners
[email protected]
SOURCE: Aytu BioPharma, Inc.
View the original press release on ACCESS Newswire
P.Silva--AMWN
